Literature DB >> 8748591

CT-guided pain procedures for intractable pain in malignancy.

Y Kanpolat1, S Caglar, S Akyar, C Temiz.   

Abstract

CT-guided stereotactic percutaneous destructive procedures, i.e. percutaneous cordotomy, trigeminal tractotomy, and extralemniscal myelotomy, have been routinely used for the treatment of localized intractable pain in malignancy since 1987. In 67 cases if local pain due to malignancy, CT guided percutaneous cordotomy was performed and in 97% complete pain control was achieved. In 45 of these cases, a "selective cordotomy" was performed meaning that analgesia was produced only in the painful region of the body. CT guided trigeminal tractotomy was applied to a total of 19 cases in 5 of which pain had been caused by malignancy. The results were satisfactory. 12 cases, suffering from visceral pain due to malignancy, were treated by CT-guided extralemniscal myelotomy and in 10 cases pain relief was achieved.

Entities:  

Mesh:

Year:  1995        PMID: 8748591     DOI: 10.1007/978-3-7091-9419-5_19

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  3 in total

1.  European Society for Stereotactic and Functional Neurosurgery. Milan, Italy, June 12-15, 1996. Abstracts.

Authors: 
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

2.  Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Neuroablative Procedures for Patients With Cancer Pain.

Authors:  Ahmed M Raslan; Sharona Ben-Haim; Steven M Falowski; André G Machado; Jonathan Miller; Julie G Pilitsis; William S Rosenberg; Joshua M Rosenow; Jennifer Sweet; Ashwin Viswanathan; Christopher J Winfree; Jason M Schwalb
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

3.  Current aproach to cancer pain management: Availability and implications of different treatment options.

Authors:  Hrachya Nersesyan; Konstantin V Slavin
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.